Invesco Ltd. Acquires 186,087 Shares of Phibro Animal Health Corporation $PAHC

Key Points

• Invesco Ltd. significantly increased its stake in Phibro Animal Health Corporation by 92.3%, owning 387,739 shares valued at approximately $8.3 million.
• Research analysts have recently upgraded Phibro Animal Health's ratings, with JPMorgan Chase raising their price target from $25 to $35.
• Phibro Animal Health announced a quarterly dividend of $0.12 per share, which equates to an annual yield of 1.5% for shareholders.

Invesco Ltd. boosted its position in Phibro Animal Health Corporation (NASDAQ:PAHC - Free Report) by 92.3% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 387,739 shares of the company's stock after acquiring an additional 186,087 shares during the period. Invesco Ltd. owned 0.96% of Phibro Animal Health worth $8,282,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Phibro Animal Health in the fourth quarter worth approximately $29,000. National Bank of Canada FI purchased a new position in Phibro Animal Health during the first quarter valued at $30,000. Lazard Asset Management LLC lifted its position in Phibro Animal Health by 2,739.7% during the fourth quarter. Lazard Asset Management LLC now owns 1,647 shares of the company's stock valued at $34,000 after buying an additional 1,589 shares during the period. Virtus Fund Advisers LLC purchased a new position in Phibro Animal Health during the fourth quarter valued at $69,000. Finally, Aquatic Capital Management LLC purchased a new position in Phibro Animal Health during the fourth quarter valued at $69,000. 99.34% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

PAHC has been the subject of several recent research reports. Wall Street Zen raised Phibro Animal Health from a "hold" rating to a "buy" rating in a research report on Friday, May 9th. JPMorgan Chase & Co. upgraded Phibro Animal Health from a "neutral" rating to an "overweight" rating and raised their price target for the company from $25.00 to $35.00 in a report on Monday, July 7th. BNP Paribas upgraded Phibro Animal Health to a "hold" rating in a report on Monday, June 16th. Morgan Stanley set a $26.00 price target on Phibro Animal Health and gave the company an "equal weight" rating in a report on Wednesday, June 25th. Finally, BNP Paribas Exane upgraded Phibro Animal Health from an "underperform" rating to a "neutral" rating and set a $24.00 price target for the company in a report on Monday, June 16th. One equities research analyst has rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Reduce" and an average price target of $24.40.

Phibro Animal Health Price Performance

NASDAQ PAHC traded up $6.26 during trading hours on Thursday, reaching $38.46. The company's stock had a trading volume of 1,069,800 shares, compared to its average volume of 268,053. The firm's 50-day moving average price is $29.07 and its 200-day moving average price is $24.38. The company has a quick ratio of 1.23, a current ratio of 2.91 and a debt-to-equity ratio of 2.67. Phibro Animal Health Corporation has a 1 year low of $16.16 and a 1 year high of $38.83. The company has a market capitalization of $1.56 billion, a price-to-earnings ratio of 32.59, a PEG ratio of 0.54 and a beta of 0.80.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last released its quarterly earnings data on Wednesday, August 27th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.52 by $0.05. Phibro Animal Health had a return on equity of 33.03% and a net margin of 3.73%.The business had revenue of $378.70 million for the quarter, compared to the consensus estimate of $362.24 million. Phibro Animal Health has set its FY 2026 guidance at 2.520-2.700 EPS. On average, equities research analysts predict that Phibro Animal Health Corporation will post 1.95 EPS for the current fiscal year.

Phibro Animal Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 24th. Shareholders of record on Wednesday, September 3rd will be paid a $0.12 dividend. The ex-dividend date of this dividend is Wednesday, September 3rd. This represents a $0.48 dividend on an annualized basis and a yield of 1.2%. Phibro Animal Health's payout ratio is presently 61.54%.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.